Last reviewed · How we verify

Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. — Portfolio Competitive Intelligence Brief

Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. pipeline: 0 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 0 Phase 2 2 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
FHND9041 FHND9041 phase 3 Unknown Unknown Unknown

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Abdi Ibrahim Ilac San. ve Tic A.S. · 1 shared drug class
  2. Ahn-Gook Pharmaceuticals Co.,Ltd · 1 shared drug class
  3. Beijing Tiantan Hospital · 1 shared drug class
  4. Bursa Yuksek Ihtisas Training and Research Hospital · 1 shared drug class
  5. Dongkook Pharmaceutical Co., Ltd. · 1 shared drug class
  6. GlaxoSmithKline · 1 shared drug class
  7. Gloucestershire Hospitals NHS Foundation Trust · 1 shared drug class
  8. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd.:

Cite this brief

Drug Landscape (2026). Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/jiangsu-chia-tai-fenghai-pharmaceutical-co-ltd. Accessed 2026-05-17.

Related